Pulmonary vascular disease & thromboembolism
Worldwide Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Registry: Long-Term Outcomes With Pulmonary Endarterectomy, Balloon Pulmonary Angioplasty, and Medical Therapy
Authors' conclusion
This second international CTEPH registry reveals important improvement in patient survival since the introduction of BPA and an approved drug for pulmonary hypertension. The type of anticoagulation regimen did not influence survival.
Study context
- Population
- Newly diagnosed CTEPH, 34 centres in 20 countries, enrolled Feb 2015–Sep 2016, followed until Sep 2019
- Participants
- 1,009 consecutive patients
- Exposure
- Pulmonary endarterectomy (PEA) vs balloon pulmonary angioplasty (BPA) vs no PEA/BPA
- PEAn = 605
- BPAn = 185
- No PEA/BPAn = 219
- Outcome
- Death during observation period
- Follow-up
- >3 years; ≤5.6 years
Methodological detailsinternational, 34 centres in 20 countries, consecutive patients
- International
- 34 centres in 20 countries
- Consecutive patients
Main finding
As reported in the abstract
Death during observation period · >3 years; ≤5.6 years
3-year survival (Kaplan-Meier)
- PEA vs BPA: P < 0.001 — death across the 3 groups
Observational data: associations, not effects.
Further findings
| Outcome | P value |
|---|---|
| Survival by anticoagulant (VKA vs NOAC)No survival difference | P = 0.756 |
Original publication
Worldwide CTEPH Registry: Long-Term Outcomes With Pulmonary Endarterectomy, Balloon Pulmonary Angioplasty, and Medical Therapy. Circulation. Published 17 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →